Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
| Title : Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis - Zhang_2014_Proc.Natl.Acad.Sci.U.S.A_111_11127 |
| Author(s) : Zhang G , Panigrahy D , Hwang SH , Yang J , Mahakian LM , Wettersten HI , Liu JY , Wang Y , Ingham ES , Tam S , Kieran MW , Weiss RH , Ferrara KW , Hammock BD |
| Ref : Proc Natl Acad Sci U S A , 111 :11127 , 2014 |
| Abstract : Zhang_2014_Proc.Natl.Acad.Sci.U.S.A_111_11127 |
| ESTHER : Zhang_2014_Proc.Natl.Acad.Sci.U.S.A_111_11127 |
| PubMedSearch : Zhang_2014_Proc.Natl.Acad.Sci.U.S.A_111_11127 |
| PubMedID: 25024195 |
| Title : Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB - Wecksler_2014_Anticancer.Drugs_25_433 |
| Author(s) : Wecksler AT , Hwang SH , Wettersten HI , Gilda JE , Patton A , Leon LJ , Carraway KL, 3rd , Gomes AV , Baar K , Weiss RH , Hammock BD |
| Ref : Anticancer Drugs , 25 :433 , 2014 |
| Abstract : Wecksler_2014_Anticancer.Drugs_25_433 |
| ESTHER : Wecksler_2014_Anticancer.Drugs_25_433 |
| PubMedSearch : Wecksler_2014_Anticancer.Drugs_25_433 |
| PubMedID: 24525589 |
| Title : Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy - Inoue_2011_Cancer.Biol.Ther_12_827 |
| Author(s) : Inoue H , Hwang SH , Wecksler AT , Hammock BD , Weiss RH |
| Ref : Cancer Biol Ther , 12 :827 , 2011 |
| Abstract : Inoue_2011_Cancer.Biol.Ther_12_827 |
| ESTHER : Inoue_2011_Cancer.Biol.Ther_12_827 |
| PubMedSearch : Inoue_2011_Cancer.Biol.Ther_12_827 |
| PubMedID: 21878748 |
| Title : Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo - Liu_2009_Mol.Cancer.Ther_8_2193 |
| Author(s) : Liu JY , Park SH , Morisseau C , Hwang SH , Hammock BD , Weiss RH |
| Ref : Mol Cancer Ther , 8 :2193 , 2009 |
| Abstract : Liu_2009_Mol.Cancer.Ther_8_2193 |
| ESTHER : Liu_2009_Mol.Cancer.Ther_8_2193 |
| PubMedSearch : Liu_2009_Mol.Cancer.Ther_8_2193 |
| PubMedID: 19671760 |
| Title : Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model - Ulu_2008_J.Cardiovasc.Pharmacol_52_314 |
| Author(s) : Ulu A , Davis BB , Tsai HJ , Kim IH , Morisseau C , Inceoglu B , Fiehn O , Hammock BD , Weiss RH |
| Ref : J Cardiovasc Pharmacol , 52 :314 , 2008 |
| Abstract : Ulu_2008_J.Cardiovasc.Pharmacol_52_314 |
| ESTHER : Ulu_2008_J.Cardiovasc.Pharmacol_52_314 |
| PubMedSearch : Ulu_2008_J.Cardiovasc.Pharmacol_52_314 |
| PubMedID: 18791465 |
| Title : Vascular localization of soluble epoxide hydrolase in the human kidney - Yu_2004_Am.J.Physiol.Renal.Physiol_286_F720 |
| Author(s) : Yu Z , Davis BB , Morisseau C , Hammock BD , Olson JL , Kroetz DL , Weiss RH |
| Ref : American Journal of Physiology Renal Physiol , 286 :F720 , 2004 |
| Abstract : Yu_2004_Am.J.Physiol.Renal.Physiol_286_F720 |
| ESTHER : Yu_2004_Am.J.Physiol.Renal.Physiol_286_F720 |
| PubMedSearch : Yu_2004_Am.J.Physiol.Renal.Physiol_286_F720 |
| PubMedID: 14665429 |
| Title : Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation - Davis_2002_Proc.Natl.Acad.Sci.U.S.A_99_2222 |
| Author(s) : Davis BB , Thompson DA , Howard LL , Morisseau C , Hammock BD , Weiss RH |
| Ref : Proc Natl Acad Sci U S A , 99 :2222 , 2002 |
| Abstract : Davis_2002_Proc.Natl.Acad.Sci.U.S.A_99_2222 |
| ESTHER : Davis_2002_Proc.Natl.Acad.Sci.U.S.A_99_2222 |
| PubMedSearch : Davis_2002_Proc.Natl.Acad.Sci.U.S.A_99_2222 |
| PubMedID: 11842228 |